M. Fisher

发表

Effects of torcetrapib in patients at high risk for coronary events.

M. Caulfield, S. Grundy, P. Barter, 2007, The New England journal of medicine.

Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease.

M. Pfeffer, C. O'connor, M. Fisher, 2006, American heart journal.

The Role of an Independent Statistical Analysis Center in the Industry-Modified National Institutes of Health Model

D. DeMets, M. Fisher, E. Roecker, 2001 .

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

Christopher M O'Connor, C. O'connor, M. Fisher, 2003, JAMA.

Coronary Intervention Study

I., M. Fisher, S. Kelsey, 2005 .

Relationship between rate of patient enrollment and quality of clinical center performance in two multicenter trials in ophthalmology.

B. Hawkins, M. Fisher, D. Blackhurst, 1990, Controlled clinical trials.

Sample sizes for long-term medical trial with time-dependent dropout and event rates.

D. DeMets, M. Fisher, M. Wu, 1980, Controlled clinical trials.

The WIZARD Trial as a Case Study of Flexible Clinical Trial Design

Thomas D. Cook, Rebecca J. Benner, Marian R. Fisher, 2006 .

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.

M. Fisher, S. Kelsey, K. Detre, 1984, Circulation.

A diet history questionnaire ranks nutrient intakes in middle-aged and older men and women similarly to multiple food records.

R. Klein, B. Klein, J. Freudenheim, 1993, The Journal of nutrition.